References
- Yang Y, Xiong L, Li M, Jiang P, Wang J, Li C. Advances in radiotherapy and immunity in hepatocellular carcinoma. Vol. 21, Journal of Translational Medicine. BioMed Central Ltd; 2023.
- Watson J, Hydon K, Lodge P. Primary and secondary liver tumours. InnovAiT: Education and inspiration for general practice. 2016 Aug;9(8):477–82.
- Amini M, Looha MA, Zarean E, Pourhoseingholi MA. Global pattern of trends in incidence, mortality, and mortality-to-incidence ratio rates related to liver cancer, 1990–2019: a longitudinal analysis based on the global burden of disease study. BMC Public Health. 2022 Dec 1;22(1).
- Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022 Jan;161:108–18.
- Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023 Aug;79(2):516–37.
- Sadikin BG. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Karsinoma Sel Hati Pada Dewasa. 1st ed. Vol. 1. Jakarta: Keputusan Menteri Kesehatan Republik Indonesia; 2022. 1–122 p.
- Cancer Today [Internet]. [cited 2024 Feb 22]. Available from:
https://gco.iarc.fr/today/en - Liver Cancer Treatment - NCI [Internet]. [cited 2024 Feb 22]. Available from:
https://www.cancer.gov/types/liver/what-is-liver-cancer/treatment - Benson AB, D’Angelica MI, Abrams T, Abbott DE, Ahmed A, Anaya DA, et al. NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023. Journal of the National Comprehensive Cancer Network. 2023 Jul;21(7):694–704.
- Chen CP. Role of radiotherapy in the treatment of hepatocellular carcinoma. Vol. 7, Journal of Clinical and Translational Hepatology. Xia and He Publishing Inc.; 2019. p. 183–90.
- Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. Vol. 27, World Journal of Gastroenterology. Baishideng Publishing Group Co; 2021. p. 2434–57.
- Kimura T, Fujiwara T, Kameoka T, Adachi Y, Kariya S. The Current Role of Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC). Vol. 14, Cancers. MDPI; 2022.
- Gordan JD, Kennedy EB, Ghassan ;, Abou-Alfa K, Muhammad ;, Beg S, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol [Internet]. 2020;38:4317–45. Available from: https://doi.
- Vogel A, Martinelli E, Cervantes A, Chau I, Daniele B, Llovet JM, et al. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Vol. 32, Annals of Oncology. Elsevier Ltd; 2021. p. 801–5.
- Rio E, Mornex F, Maingon P, Peiffert D, Parent L. Hepatic tumours and radiotherapy. Cancer Radiother. 2022;26(1–2):266–71.
- Hunte SO, Clark CH, Zyuzikov N, Nisbet A. Volumetric modulated arc therapy (VMAT): a review of clinical outcomes—what is the clinical evidence for the most effective implementation? Vol. 95, British Journal of Radiology. British Institute of Radiology; 2022.
- Koay EJ, Owen D, Das P. Radiation-Induced Liver Disease and Modern Radiotherapy. Vol. 28, Seminars in Radiation Oncology. W.B. Saunders; 2018. p. 321–31.
- Kalogeridi MA, Zygogianni A, Kyrgias G, Kouvaris J, Chatziioannou S, Kelekis N, et al. Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol. 2015;7(1):101–12.
- Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski P, Clavien PA. Modern therapeutic approaches for the treatment of malignant liver tumours. Vol. 17, Nature Reviews Gastroenterology and Hepatology. Nature Research; 2020. p. 755–72.
- Navin PJ, Olson MC, Mendiratta-Lala M, Hallemeier CL, Torbenson MS, Venkatesh SK. Imaging Features in the Liver after Stereotactic Body Radiation Therapy. Radiographics. 2022;42(7):2131–48.
- Muhammad H, Tehreem A, Ting PS, Gurakar M, Li SY, Simsek C, et al. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. J Clin Transl Hepatol. 2021;9(5):738–48.
- Shimamura T, Goto R, Watanabe M, Kawamura N, Takada Y. Liver Transplantation for Hepatocellular Carcinoma: How Should We Improve the Thresholds? 2022; Available from:
https://doi.org/10.3390/cancers14020419 - Kim N, Kim HJ, Won JY, Kim DY, Han KH, Jung I, et al. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol. 2019 Feb;131:81–7.
- Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. Journal of Clinical Oncology. 2016 Feb 10;34(5):452–9.
- Bae SH, Chun SJ, Chung JH, Kim E, Kang JK, Jang W Il, et al. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines. International Journal of Radiation Oncology Biology Physics. Elsevier Inc.; 2023.
- Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017 Jul 1;67(1):92–9.
- Dumago MP, Agas RAF, Jainar CJE, Yap ET, Co LBA, Ortin TTS. Stereotactic Body Radiation Therapy With or Without Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone in Early-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. J Gastrointest Cancer. 2023 Dec;54(4):1058–70.
- Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, et al. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surg Oncol. 2019 Mar;28:228–35.
- Shen L, Xi M, Zhao L, Zhang X, Wang X, Huang Z, et al. Combination therapy after TACE for hepatocellular carcinoma with macroscopic vascular invasion: Stereotactic body radiotherapy versus sorafenib. Cancers (Basel). 2018 Dec 1;10(12).
- Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion : A randomized clinical trial. In: JAMA Oncology. American Medical Association; 2018. p. 661–9.
- Rim CH, Lee JS, Kim SY, Seong J. Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis. JHEP Reports. 2023 Jan 1;5(1).
- Yamamoto M, Yoshida M, Furuse J, Sano K, Ohtsuka M, Yamashita S, et al. Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. J Hepatobiliary Pancreat Sci. 2021 Jan 1;28(1):1–25.
- Yoo GS, Rim CH, Cho WK, Jeong JU, Chie EK, Cho HM, et al. Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy. Cancer Res Treat. 2023 Jul 1;55(3):707–19.
- Jackson WC, Tao Y, Mendiratta-Lala M, Bazzi L, Wahl DR, Schipper MJ, et al. Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases. Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):950–8.
- Yu J, Kim DH, Lee J, Shin YM, Kim JH, Yoon SM, et al. Radiofrequency Ablation versus Stereotactic Body Radiation Therapy in the Treatment of Colorectal Cancer Liver Metastases. Cancer Res Treat. 2022 Jul 1;54(3):850–9.
- Méndez Romero A, Schillemans W, van Os R, Koppe F, Haasbeek CJ, Hendriksen EM, et al. The Dutch–Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases. Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1377–86.
- de la Peña C, Gonzalez MF, González C, Salazar JM, Cruz B. Stereotactic body radiation therapy for liver metastases: Clinical outcomes and literature review. Reports of Practical Oncology and Radiotherapy. 2020 Jul 1;25(4):637–42.
- Palma DA, Olson R, Harrow S, Gaede S, Louie A V., Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET Phase II randomized trial. Journal of Clinical Oncology. 2020;38(25):2830–8.
- Lee JW, Choi MH, Lee YJ, Ali B, Yoo HM, Song KY, et al. Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection. BMC Cancer. 2017 Mar 10;17(1).